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Objective
To explore any diﬀerences in eﬃcacy and safety outcomes
between European (EU) (n = 684) and North American (NA)
(n = 395) patients in the AFFIRM trial (NCT00974311).
Patients and Methods
Phase III, double-blind, placebo-controlled, multinational
AFFIRM trial in men with metastatic castration-resistant
prostate cancer (mCRPC) after docetaxel. Participants were
randomly assigned in a 2:1 ratio to receive oral enzalutamide
160 mg/day or placebo. The primary end point was overall
survival (OS) in a post hoc analysis.
Results
Enzalutamide signiﬁcantly improved OS compared with
placebo in both EU and NA patients. The median OS in EU
patients was longer than NA patients in both treatment
groups. However, the relative treatment eﬀect, expressed as
hazard ratio and 95% conﬁdence interval, was similar in both
regions: 0.64 (0.50, 0.82) for EU and 0.63 (0.47, 0.83) for NA.
Signiﬁcant improvements in other end points further
conﬁrmed the beneﬁt of enzalutamide over placebo in
patients from both regions. The tolerability proﬁle of
enzalutamide was comparable between EU and NA patients,
with fatigue and nausea the most common adverse events.
Four EU patients (4/461 enzalutamide-treated, 0.87%) and one
NA patient (1/263 enzalutamide-treated, 0.38%) had seizures.
The diﬀerence in median OS was related in part to the timing
of development of mCRPC and baseline demographics on
study entry.
Conclusion
This post hoc exploratory analysis of the AFFIRM trial showed
a consistent OS beneﬁt for enzalutamide in men with mCRPC
who had previously progressed on docetaxel in both NA- and
EU-treated patients, although the median OS was higher in
EU relative to NA patients. Eﬃcacy beneﬁts were consistent
across end points, with a comparable safety proﬁle in both
regions.
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Introduction
Metastatic castration-resistant prostate cancer (mCRPC),
characterised by disease progression after surgical or medical
castration, remains a chronic disease with a poor prognosis
[1]. In vitro, in vivo and proﬁling studies of human prostate
cancers show that continued activation of signalling through
the androgen receptor (AR) pathway is frequent and that the
disease remains sensitive to further hormonal treatments
[2–4]. Several new agents have shown improvements in
overall survival (OS) in patients with mCRPC previously
treated with docetaxel [5]; one is the AR inhibitor
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enzalutamide (formerly MDV3100). This once-daily, oral
hormonal treatment does not require co-administration of
prednisone and can be taken with or without food [6]. The
drug inhibits multiple steps in the AR signalling pathway,
including binding of testosterone to the AR, translocation of
the hormone/receptor complex to the nucleus and binding of
the ligand/receptor complex to DNA, inhibiting transcription
[7,8].
The approval for use of enzalutamide for patients with
mCRPC previously treated with docetaxel is based on
the results of the randomised, phase III, double-blind,
placebo-controlled, multinational AFFIRM trial
(NCT00974311), with a primary end point of OS [6]. In that
trial, enzalutamide showed a signiﬁcant beneﬁt over placebo
in OS (median OS was 18.4 months in the enzalutamide
group vs 13.6 months in the placebo group; hazard ratio [HR]
0.63; P < 0.001). The superiority of enzalutamide over placebo
was consistent for all secondary end points, including PSA
response, objective soft tissue response, health-related quality
of life (HRQL), time to PSA progression, radiographic
progression-free survival (rPFS) and time to ﬁrst
skeletal-related event (SRE) (all P < 0.001 vs placebo) [6].
Most patients (90%) in the AFFIRM trial were recruited from
Europe (EU) and North America (NA). However, clinical
management, diagnosis and treatment guidelines for prostate
cancer diﬀer between these regions. For example, detection
and screening practices in NA are more aggressive than in EU,
which may explain, in part, why the NA patients are diagnosed
with prostate cancer younger and have lower PSA levels than
EU patients [9]. Treatment patterns also diﬀer, as do the
treatment guidelines in use in each region [10–15], to which
general adherence and interpretation may also vary broadly.
How they are used in practice is also inﬂuenced by the
experience and preference of the treating centre and physician
[16,17]. Variations in the availability of new treatments,
and the time of use in practice, also exist, as does the
use of second-line chemotherapy after docetaxel and
bisphosphonates [18–23]. All of these factors, alone or
together, may explain diﬀerences in disease recurrence and
progression patterns. This post hoc exploratory analysis
of the AFFIRM trial was undertaken to explore the outcomes
of EU and NA patients enrolled in the study. The study was
not powered or designed to assess regional diﬀerences at
baseline; nevertheless, such diﬀerences may exist and aﬀect
outcomes.
Patients and Methods
The AFFIRM study design and methods have previously
been published [6]. Patients with a conﬁrmed diagnosis of
metastatic prostate cancer, castrate levels of testosterone
(<50 ng/dL, 1.7 nmol/L), previous treatment with docetaxel
and progressive disease (deﬁned by PSA, soft tissue disease or
bone disease progression) were enrolled in the AFFIRM trial
from September 2009 to November 2010. Patients were
randomly assigned to study treatment (2:1, enzalutamide
160 mg/day:placebo) after stratiﬁcation according to baseline
Eastern Cooperative Oncology Group performance status
(ECOG PS) score (0 or 1 vs 2) and the average of daily
pain scores over the 7 days before randomisation using
the Brief Pain Inventory-Short Form (BPI-SF) question 3
(<4 vs ≥4) [6].
In the present post hoc subanalysis, the primary and
secondary end points were evaluated in the patient
subgroups from both EU and NA regions and the relative
treatment eﬀect (enzalutamide vs placebo) compared. The
primary end point was OS. Subgroup analyses of OS were
conducted to determine whether treatment eﬀects were
consistent across patient subgroups including age, baseline
characteristics and previous treatment. The variable list in
the multivariate Cox proportional hazards model included
study arm, baseline ECOG PS group (0–1 vs 2), baseline
BPI-SF group (0–3 vs 4–10), type of progression at baseline
(PSA only vs radiographic), visceral disease at baseline
(‘Yes’ vs ‘No’), baseline haemoglobin (g/L), baseline lactate
dehydrogenase (U/L), geographic region (EU vs NA) and
study arm-by-geographic region interaction term. The
signiﬁcance of geographic region and interaction term was
assessed using the chi-squared test for the corresponding HR
term in the full model (region and interaction term assessed
simultaneously with all listed variables). Secondary end
points included measures of response (PSA level, objective
soft tissue response and HRQL assessed using the Functional
Assessment of Cancer Therapy-Prostate [FACT-P]
questionnaire) and measures of disease progression (time to
PSA progression, rPFS and time to ﬁrst SRE). Evaluation of
pain progression was included as an exploratory end point
(as an increase from baseline in the FACT-P pain scale). The
deﬁnitions of the end points used in this exploratory analysis
and the statistical methods used are provided in the Online
Supplementary Information in Table S1. Information on
prostate cancer treatments that patients in the two regions
received after discontinuation of enzalutamide was also
recorded. Data obtained by 25 September 2011 were
included in the analysis.
Results
This analysis included 684 EU patients and 395 NA patients.
Overall, the patient baseline characteristics were similar
between the two regions (Table 1) with some diﬀerences. For
example, the median time from initial diagnosis was shorter
for patients receiving enzalutamide in the EU (67.1 months)
compared with NA (89.9 months) and the proportion with a
lower pain score was higher (BPI-SF, question 3: < 4). A lower
proportion of EU patients had a high total Gleason score
(8–10) than NA patients (44.0% vs 50.6%). Cardiac disease
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was less prevalent in EU than NA patients, while more had
received more than two lines of prior hormonal therapy or
chemotherapy. Prior and concomitant corticosteroid use, as
well as concomitant use of bone protective agents (zoledronic
acid), was lower in EU than NA patients (Table 1).
Enzalutamide signiﬁcantly improved OS compared with
placebo in both regional groups (Fig. 1) but the median OS in
EU patients (enzalutamide, not yet reached; placebo, 16.2
months) was longer in both treatment groups compared with
NA patients (enzalutamide, 17.4 months; placebo, 12.3
months). The relative treatment eﬀect was similar across the
two regions: HRs (95% CIs) were 0.64 (0.50, 0.82) for EU
patients and 0.63 (0.47, 0.83) for NA patients. There was a
diﬀerence of 1.9 months in median duration of follow-up
(reverse Kaplan–Meier methodology) between regions (EU,
13.7 months; NA, 15.6 months), with no signiﬁcant diﬀerences
between study arms within each region. Maximal follow-up
was 21.3 months in EU and 23.2 months in NA. Analysis of
the OS data by diﬀerent subgroups showed consistent
enzalutamide beneﬁts across most subgroups in both regions
(Fig. 2). For NA patients with visceral disease at baseline,
median OS was similar with enzalutamide and placebo.
Notable, however, is that there were no regional diﬀerences
(HR 1.02; 95% CI 0.76, 1.38) or region-by-arm interaction
(HR 0.94; 95% CI 0.64, 1.38) after controlling for baseline
prognostic factors in a multivariable Cox model. Each of
the terms listed in the multivariate model was statistically
signiﬁcant (P < 0.05) except for baseline BPI-SF group
(P = 0.0577), which was a randomisation stratiﬁcation factor
and should be included in the model by study design. The
process for selection of the non-randomisation stratiﬁcation
terms (everything except ECOG PS and BPI-SF) was based on
imbalance or potential for confounding across the regions.
The fact that all terms listed were signiﬁcant and the factors
(region and region*treatment interaction) were not signiﬁcant
suggests that some of these terms were confounders to the
apparent regional diﬀerences in OS.
The beneﬁt of enzalutamide over placebo was consistent
across all secondary end points in patients in both regions,
with signiﬁcant improvements (P < 0.001) in PSA, soft tissue
and HRQL responses, time to PSA progression and rPFS
(Table 2). Similar relative treatment eﬀects (enzalutamide vs
Table 1 The patients’ baseline characteristics.
Baseline characteristic EU NA
Enzalutamide
(n = 461)
Placebo
(n = 223)
Total
(n = 684)
Enzalutamide
(n = 263)
Placebo
(n = 132)
Total
(n = 395)
Mean (SD) age, years 68.5 (7.46) 67.7 (7.88) 68.2 (7.60) 69.2 (8.70) 69.7 (9.34) 69.4 (8.91)
Median time from initial diagnosis, months 67.1 72.0 68.9 89.9 67.3 78.0
ECOG PS, n (%)
0–1 433 (93.9) 206 (92.4) 639 (93.4) 237 (90.1) 125 (94.7) 362 (91.6)
2 28 (6.1) 17 (7.6) 45 (6.6) 26 (9.9) 7 (5.3) 33 (8.4)
Pain score, n (%)
<4 339 (73.5) 169 (75.8) 508 (74.3) 186 (70.7) 88 (66.7) 274 (69.4)
≥4 122 (26.5) 54 (24.2) 176 (25.7) 77 (29.3) 44 (33.3) 121 (30.6)
Total Gleason score category, n (%)
Low (2–4) 4 (0.9) 6 (2.7) 10 (1.5) 5 (1.9) 0 (0) 5 (1.3)
Medium (5–7) 202 (43.8) 97 (43.5) 299 (43.7) 112 (42.6) 56 (42.4) 168 (42.5)
High (8–10) 201 (43.6) 100 (44.8) 301 (44.0) 131 (49.8) 69 (52.3) 200 (50.6)
Median total Gleason score 7.0 7.0 7.0 8.0 8.0 8.0
Median PSA level, ng/mL 109.5 123.1 112.5 110.2 131.2 113.6
Median LDH, U/L 208.0 207.0 208.0 212.0 219.0 213.0
Visceral disease (liver or lung), n (%) 106 (23.0) 45 (20.2) 151 (22.1) 73 (27.8) 32 (24.2) 105 (26.6)
Bone lesions, n (%)
0–≤20 292 (63.3) 146 (65.5) 438 (64.0) 161 (61.2) 77 (58.3) 238 (60.3)
>20 169 (36.7) 77 (34.5) 246 (36.0) 102 (38.8) 55 (41.7) 157 (39.7)
Cardiac disease, n (%)
NYHA class ≤III 32 (6.9) 17 (7.6) 49 (7.2) 63 (24.0) 29 (22.0) 92 (23.3)
No cardiac disease 429 (93.1) 206 (92.4) 635 (92.8) 200 (76.0) 103 (78.0) 303 (76.7)
Prior corticosteroid use, n (%)* 137 (29.7) 63 (28.3) 200 (29.2) 85 (32.3) 49 (37.1) 134 (33.9)
Prior hormonal therapy, n (%)
≤2 216 (46.9) 96 (43.0) 312 (45.6) 145 (55.1) 71 (53.8) 216 (54.7)
>2 245 (53.1) 127 (57.0) 372 (54.4) 118 (44.9) 61 (46.2) 179 (45.3)
Mean LHRH duration, months 25.9 27.6 26.4 27.2 27.3 27.2
Prior chemotherapy, n (%)
1 330 (71.6) 158 (70.9) 488 (71.3) 190 (72.2) 102 (77.3) 292 (73.9)
≥2 131 (28.4) 65 (29.1) 196 (28.7) 73 (27.8) 30 (22.7) 103 (26.1)
LDH, lactate dehydrogenase; LHRH, luteinising hormone-releasing hormone; NYHA, New York Heart Association. *Based on medical review to identify oral systemic corticosteroids for
prostate cancer.
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placebo) were seen for both regions, except for time to ﬁrst
SRE where a signiﬁcant improvement with enzalutamide was
only seen in EU patients. Kaplan–Meier curves showing the
beneﬁts of enzalutamide vs placebo in both EU and NA
patients for time to PSA progression, rPFS, time to ﬁrst SRE
and time to pain progression are available in the Online
Supplementary Information in Figs. S1–S4.
Although similar proportions of patients received a
subsequent line of therapy on disease progression, the speciﬁc
therapies administered were diﬀerent in the two regions
(Table 3). Speciﬁcally, more EU than NA patients randomised
to placebo subsequently received abiraterone (30.5% vs
19.7%), whereas patients randomised to enzalutamide had
similar subsequent exposure to abiraterone (21.7% EU vs
22.8% NA). Fewer EU than NA patients received cabazitaxel
after enzalutamide (6.5% vs 15.6%) and after placebo (9.9%
vs 20.5%).
The overall safety proﬁle of enzalutamide vs placebo
was similar between the two regions (Table 4) for the
overall number of adverse events (AEs)/serious AEs.
Enzalutamide-treated patients in EU and NA had a lower
incidence of AEs of grade ≥3 vs placebo. A slightly lower rate
of discontinuations due to AEs was seen in the EU group.
AEs of interest included seizure (four [0.87%] EU patients
and one [0.38%] NA patient [Table 4]). Nausea, fatigue,
anorexia, back pain, constipation and diarrhoea were
reported by ≥20% of patients in both EU and NA (Online
Supplementary Information Table S2). Nausea occurred at an
incidence of 28% (enzalutamide) vs 39% (placebo) in EU
and 40% (enzalutamide) vs 43% (placebo) in NA. Incidence
of fatigue was 25% (enzalutamide) vs 22% (placebo) in EU
and 48% (enzalutamide) vs 42% (placebo) in NA. Hot ﬂushes
occurred in enzalutamide patients at a rate ≥5% over placebo
for both EU and NA patients. There were some diﬀerences
between the regions in the incidence of speciﬁc AEs. For
the NA enzalutamide group, several AEs occurred at an
incidence ≥5% over placebo, including fatigue, diarrhoea,
arthralgia, headache and muscular weakness, whereas in the
EU enzalutamide group the incidence of these events was
similar to placebo.
Discussion
Diﬀerences in prostate cancer diagnosis and treatment
patterns exist between EU and NA. The present post hoc
exploratory analysis was performed to assess the outcomes
of patients treated in the phase III registration trial of
enzalutamide vs placebo (AFFIRM) in EU and NA,
recognising that the study was not powered or designed to
assess (or account for) regional diﬀerences at baseline. The
results showed that the OS beneﬁt provided by enzalutamide
relative to placebo was of the same degree in men with
mCRPC who had progressed on docetaxel in both regions.
The results are consistent with the ﬁndings for the overall
study population reported previously [6].
A similar outcome was seen for all secondary end points
analysed, which included a range of early measures of
response and progression as per the recommendations of the
Prostate Cancer Clinical Trials Working Group 2 [24]. The
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Placebo HR 0.63; 95% CI 0.47, 0.83
Europe
HR 0.64; 95% CI 0.50, 0.82
Months
No. at risk
15 18 21 24
1 445461 411 367 218 110 34 2 0
2 256263 224 202 140 77 28 3 0
4 122132 98 83 61 34 13 0
3 212223 185 151 85 37 16 2 0
Fig. 1 OS (unadjusted assessment) by region
and by arm.
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same parallel improvements in OS and in all secondary end
points analysed is consistent with the results reported with
other approved agents for post-chemotherapy treated mCRPC.
Considering OS, the HR (95% CI) was 0.68 (0.56, 0.83) for NA
and 0.80 (0.64, 1.00) for other regions, in the ﬁnal analysis
of abiraterone acetate plus prednisone vs placebo plus
prednisone (COU-AA-301) [25,26]. Overall OS and PFS
results in the phase III trial of cabazitaxel were also
comparable with the subgroup analysis of 90 patients from
French centres [27].
Since the advent of PSA-based detection and screening there
has been a shift towards diagnosis at an earlier stage and
grade. In a study of men with clinically localised prostate
Fig. 2 Forest plots of OS by subgroup and by region. HRs are based on a non-stratified proportional-hazards model. Dashes indicate that the median
time to death had not been reached for the indicated subgroup.The size of the circles is proportional to the size of the subgroup.The horizontal bars
represent 95% CIs. Enza, enzalutamide; LDH, lactate dehydrogenase.
Subgroup 
Age
≥65 years
Baseline ECOG PS
Baseline mean pain score
No. previous hormonal treatments
No. previous chemotherapy regimens
Type of progression at study entry
± PSA progression
HR (95% CI)
0.61 (0.43, 0.85) 
No.
patients 
273
Enza
18.2
Placebo
13.0
North America
Median OS
(months) 
Europe
No.
patients
475
Enza
18.8
Placebo
14.4
HR (95% CI)
0.64 (0.48, 0.86) 
All patients 0.63 (0.47, 0.83) 395 17.4 12.3684 – 16.2 0.64 (0.50, 0.82) 
Median OS
(months) 
No. bone lesions
1 2 3
Placebo
better
Enza
better
0.0 1.0 1.5 2.0
Placebo
better
Enza
better
0.50
Radiographic progression 0.59 (0.42, 0.84)242 16.9 11.6381 17.3 13.5 0.68 (0.50, 0.92) 
>2 0.66 (0.42, 1.03) 179 18.2 14.4372 18.3 17.7 0.69 (0.50, 0.96) 
1 0.61 (0.43, 0.85) 292 – 13.2 488 – 16.2 0.56 (0.42, 0.76) 
≥2 0.64 (0.37, 1.09) 103 14.7 11.1196 17.3 14.4 0.85 (0.55, 1.33) 
PSA progression only 0.67 (0.41, 1.09) 153 – 13.6298 – – 0.61 (0.40, 0.93) 
≥4 0.82 (0.51, 1.30)121 13.0 10.0176 11.8 9.9 0.70 (0.47, 1.05) 
≤2 0.62 (0.43, 0.90)214 15.4 9.9310 – 14.8 0.60 (0.42, 0.87) 
<4 0.56 (0.39, 0.80) 274 – 13.2508 – 19.2 0.59 (0.43, 0.81) 
0–1 0.61 (0.45, 0.82) 362 18.2 12.3639 – 17.6 0.66 (0.50, 0.85) 
2 0.68 (0.24, 1.89) 33 13.6 9.745 7.8 6.1 0.59 (0.29, 1.22)
<65 years 0.67 (0.40, 1.12) 122 14.9 10.6209 – – 0.61 (0.39, 0.97) 
≤20 17.7–438 0.55 (0.39, 0.77) 15.5–238 0.63 (0.42, 0.93)
≤Median 19.2–341 0.64 (0.43, 0.97) 15.8–196 0.73 (0.47, 1.15)
≤Median 19.2–354 0.55 (0.35, 0.86) 19.1–187 0.79 (0.48, 1.29)
Visceral (liver or lung) disease 
at baseline 
17.6–533 0.63 (0.47, 0.84) 12.4–290 0.47 (0.34, 0.67)No
10.216.5151 0.64 (0.39, 1.03) 9.69.5105 1.12 (0.66, 1.89)Yes
Baseline PSA
10.515.4343 0.63 (0.46, 0.86) 9.514.7199 0.58 (0.40, 0.84)>Median
Baseline LDH
8.512.2329 0.63 (0.47, 0.85) 8.613.0208 0.58 (0.40, 0.82)>Median
Prior corticosteroid use
–18.8408 0.67 (0.48, 0.92) 12.218.2165 0.53 (0.34, 0.82)No
14.4–276 0.62 (0.43, 0.90) 12.317.0230 0.70 (0.48, 1.02)Yes
10.413.4246 0.76 (0.53, 1.10) 8.013.0157 0.62 (0.41, 0.93)>20
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cancer treated with radical prostatectomy in EU and NA in
the past 20 years, stage and grade shifts over time were
diﬀerent in the two regions, which may be due to diﬀerent
surgical practices or diﬀerences in prostate cancer
characteristics (e.g. biopsy, Gleason sum) between the regions
[9]. Historically, management of low-risk localised disease is
more conservative in EU, with a more radical treatment
approach in NA [28]. More broadly, there are diﬀerences
between the regions in medical/health-economic systems. In
contrast to NA, EU health care is typically socialised and
patients do not usually pay for expensive new cancer drugs.
The median OS in both enzalutamide and placebo arms was
longer in EU than NA patients (enzalutamide, not yet reached
[EU] and 17.4 months [NA]; placebo, 16.2 months [EU] and
12.3 months [NA]). Potential, albeit unproven, explanations
for this observation include diﬀerences in baseline
characteristics and treatment patterns between the regions.
These diﬀerences include lower pain scores and a lesser
presence of cardiac disease in EU patients, and higher use of
prior and concomitant systemic corticosteroids, thought to
reﬂect more extensive illness [29], and concomitant use of
bone protective agents, in the NA group. Use of more than
two lines of previous hormonal therapy or chemotherapy was
also identiﬁed in more EU patients at baseline. Further
exploration of these diﬀerences was limited by the small
sample sizes of the various subgroups. The diﬀering baseline
severity across the regions (Table 1) could be evidence for
lead-time bias and partially explain the observed diﬀerences in
OS. Further diﬀerences in outcome could be related to the
time when chemotherapy was oﬀered, whether steroids were
continued or not, and when physicians considered protocol
therapy. In addition, some diﬀerences were seen in post-study
treatment, e.g. higher cabazitaxel use in NA, perhaps reﬂecting
Table 2. Secondary end points: response and progression.
Response
EU NA
Enzalutamide (n = 461) Placebo (n = 223) Enzalutamide (n = 263) Placebo (n = 132)
% of patients
Patients with ≥1 post-baseline PSA assessment 92.6 85.2 89.0 78.0
Decrease ≥50%* 55.0 1.6 51.3 1.9
Decrease ≥90%* 23.0 1.1 26.9 1.0
Patients with measurable disease 53.6 52.9 58.6 52.3
CR or PR* 29.1 5.1 26.6 2.9
Patients with ≥1 post-baseline HRQL assessment† 81.6 67.3 81.4 56.8
HRQL response* 44.1 18.7 42.1 17.3
Progression
End point EU NA
Enzalutamide
(n = 461)
Placebo
(n = 223)
HR Enzalutamide
(n = 263)
Placebo
(n = 132)
HR
Median (95% CI):
Time to PSA progression, months 8.2 (5.7, 8.3) 3.0 (2.8, 3.7) 0.28* (0.22, 0.36) 8.3 (5.8, 8.4) 3.7 (3.0, 5.6) 0.26* (0.17, 0.40)
rPFS, months 8.5 (8.2, 10.5) 2.9 (2.8, 4.5) 0.38* (0.32, 0.47) 8.3 (5.9, 9.7) 2.9 (2.8, 3.6) 0.43* (0.34, 0.55)
Time to ﬁrst SRE, months 17.4 (14.1, NYR) 11.9 (9.0, 15.2) 0.56* (0.43, 0.73) 16.7 (13.6, NYR) 18.2 (8.6, NYR) 0.79†† (0.56, 1.12)
CR, complete response; NYR, not yet reached; PR, partial response. *P < 0.001 for enzalutamide vs placebo. †Functional Assessment of Cancer Therapy-Prostate questionnaire.
††P = 0.185 for enzalutamide vs placebo.
Table 3 Subsequent therapy on disease progression.
EU NA
Enzalutamide (n = 461) Placebo (n = 223) Enzalutamide (n = 263) Placebo (n = 132)
Therapy % of patients
Total 41.0 62.3 46.4 61.4
Abiraterone acetate 21.7 30.5 22.8 19.7
Cabazitaxel 6.5 9.9 15.6 20.5
Docetaxel 8.9 15.7 8.7 15.2
Mitoxantrone 2.0 9.9 1.9 6.8
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the availability of cabazitaxel in NA before EU. Furthermore,
identifying putative confounders that negate the apparent
diﬀerences in OS between the regions neither implies such
diﬀerences do not exist, nor that the regional variations in
clinical practice do not drive diﬀerences in these confounders,
thereby having implications on survival rates between the two
regions. As our present results are based on a post hoc analysis
and the AFFIRM study was not designed to investigate
regional diﬀerence, our analysis cannot provide a deﬁnitive
answer.
Diﬀerences were also seen between the regions in the
secondary end point of time to ﬁrst SRE, although the HR was
<1 for both regions. Enzalutamide signiﬁcantly improved
median time to ﬁrst SRE compared with placebo in EU
patients (17.4 vs 11.9 months; P < 0.001), whereas there was
no signiﬁcant improvement in NA patients (16.7 vs 18.2
months; P = 0.185). The higher concomitant use of bone
protective agents by NA patients (zoledronic acid: EU 35.2%;
NA 48.6%) may have had some inﬂuence on this. The
observed diﬀerences in baseline characteristics most likely
reﬂect diagnosis and management practice patterns in the
earlier stages of the disease noted above, most of which would
have occurred sometime before patients developed CRPC,
making it diﬃcult to fully assess the likely impact on the
results seen.
The tolerability proﬁle of enzalutamide vs placebo was
generally comparable between the two regions and consistent
with tolerability in the overall AFFIRM trial population [6].
Hot ﬂushes were reported at a higher rate with enzalutamide
than placebo (≥5% diﬀerence) in both EU and NA patients,
consistent with reports from the original AFFIRM analysis [6].
The apparent diﬀerence between the regions in the incidence
of fatigue (>5% between enzalutamide and placebo in NA
patients but not in EU patients) may be due to an artefact of
the reported verbatim keywords (e.g. ‘fatigue’ vs ‘asthenia’)
used in the two regions to describe general fatigue symptoms
but resulting in diﬀerent Medical Dictionary for Regulatory
Activities codes. Another possibility is that increased rates of
fatigue in NA patients were related to higher baseline use of
steroids. Cases of seizure were reported in a small number
of patients (four EU patients [0.87%] and one NA patient
[0.38%] taking enzalutamide).
In conclusion, enzalutamide signiﬁcantly prolonged survival in
EU and NA men with mCRPC after docetaxel. The observed
treatment beneﬁt and safety proﬁle from the two regions were
consistent with the overall ﬁndings from the AFFIRM study.
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